Rivastigmine tartrate

SKU: orb1307975

Description

Rivastigmine tartrate (SDZ-ENA 713) is a centrally-acting, reversible cholinesterase inhibitor used in dementia research for Alzheimer's and Parkinson's diseases. Its application extends to in vitro enzyme assays and in vivo models to study cognitive enhancement and neuroprotection.

Research Area

Neuroscience, Pharmacology & Drug Discovery

Key Properties

• CAS Number: 129101-54-8
• MW: 400.43
• Purity: 99.91% (May vary between batches)
• Formula: C₁₄H₂₂N₂O₂·C₄H₆O₆
• SMILES: O[C@H]([C@@H](O)C(O)=O)C(O)=O.CCN(C)C(=O)Oc1cccc(c1)[C@H](C)N(C)C
• Target: AChR,Cholinesterase (ChE)
• Solubility: H2O:73 mg/mL (182.3 mM);DMSO:39 mg/mL (97.4 mM);Ethanol:74 mg/mL (184.8 mM)

Bioactivity

• Target IC50:
  AChR:5.5 μM

Storage & Handling

• Storage: -20°C
• Expiration Date: 12 months from date of receipt.
• Disclaimer: For research use only

Alternative Names

SDZ-ENA 713, SDZ-ENA-713, SDZ-ENA713, Rivastigmine, Rivastigmine tartrate, Rivastigmine Tartrate, Inhibitor, inhibit, orally, Parkinson's, parasympathomimetic, ENA 713, ENA713, ENA-713, disease, ChE, Cholinesterase (ChE), cholinesterase, cholinergic, BBB, BChE, butyrylcholinesterase, Alzheimer's, AChR, AChE, acetylcholinesteras

Compound Identifiers

PubChem CID

6918078